Leflunomide Elvim

Leflunomide, the active ingredient in Leflunomide Elvim, is an immunomodulatory agent (DMARD) presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomide Elvim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is used to modify disease activity in inflammatory arthritides, particularly within the rheumatoid and psoriatic arthritis families. - Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Inadequate response to methotrexate: provides an alternative disease‑modifying option.

Leflunomide may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any emerging symptoms.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Elevated liver enzymes: mild transaminase rise. - Hypertension: new‑onset or worsening blood pressure. - Rash: non‑specific skin irritation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatic failure. - Bone marrow suppression: neutropenia, anaemia, thrombocytopenia. - Pulmonary toxicity: interstitial lung disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Infections: opportunistic or serious bacterial infections. - Teratogenicity: risk of fetal malformations.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Liver monitoring: obtain baseline and periodic liver function tests. - Hematology monitoring: perform regular complete blood counts. - Hepatic impairment: avoid use in patients with severe liver disease. - Pregnancy: contraindicated in pregnancy; advise effective contraception. - Hypertension: monitor blood pressure regularly. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Leflunomide can alter the pharmacokinetics of several co‑administered medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: heightened toxicity, especially hepatic. - Cholesterol‑binding resins (e.g., cholestyramine): markedly reduces leflunomide exposure. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: possible increased leflunomide levels. - Statins: modest increase in statin concentrations. - Oral contraceptives: reduced efficacy, consider alternative contraception.